InflaRx's Izicopan Shows No Time-Dependent CYP3A4 Inhibition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2026
0mins
Should l Buy IFRX?
Source: Newsfilter
- Reduced Drug Interaction Risk: InflaRx's izicopan demonstrates no time-dependent inhibition of CYP3A4 even at the highest concentration of 100 µM in in vitro studies, indicating a lower risk of drug-drug interactions and liver toxicity in clinical applications.
- Mechanistic Study Support: The Ki/Kinact study confirms that izicopan does not inhibit CYP3A4 (IC₅₀ > 100 µM), further validating its safety in drug metabolism and enhancing its potential as a best-in-class oral C5aR inhibitor.
- Positive Clinical Data: In clinical trials involving patients with hidradenitis suppurativa, izicopan significantly reduced abscesses and nodules over four weeks, demonstrating biologic-like efficacy and further solidifying its market competitiveness.
- Scientific Leadership: Prof. Renfeng Guo, Chief Scientific Officer, emphasized that izicopan's unique pharmacological profile and favorable metabolic stability provide significant clinical application potential across various inflammatory diseases, potentially offering safer treatment options for patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IFRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IFRX
Wall Street analysts forecast IFRX stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 2.650
Low
6.00
Averages
12.67
High
24.00
Current: 2.650
Low
6.00
Averages
12.67
High
24.00
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
InflaRx Completes $150 Million Underwritten Offering
- Offering Size: InflaRx N.V. has completed an underwritten offering of 75 million ordinary shares at $2.00 per share, raising a total of $150 million, which reflects strong market confidence in its anti-inflammatory therapies.
- Use of Proceeds: The net proceeds from this offering will be utilized to advance the company's pipeline activities and for general corporate purposes, indicating a proactive expansion strategy aimed at accelerating drug development.
- Investor Participation: The financing attracted participation from both new and existing investors, including TCGX and Farallon Capital, which underscores market recognition of InflaRx's growth potential and strengthens its capital base.
- Underwriting Team: Guggenheim Securities acted as the lead bookrunner for the offering, with Oppenheimer & Co. and LifeSci Capital also participating, demonstrating the company's robust support network in the capital markets.
See More
InflaRx Scheduled to Announce Q1 Earnings on May 7
- Earnings Announcement: InflaRx (IFRX) is set to announce its Q1 earnings on May 7 before market open, with consensus EPS estimate at -$0.17 and revenue estimate at $0.01 million, indicating cautious market sentiment regarding the company's financial performance.
- Historical Performance Review: Over the past year, InflaRx has failed to meet EPS estimates 100% of the time and has only met revenue estimates 25% of the time, highlighting challenges in profitability and revenue growth that could impact investor confidence.
- Estimate Revision Dynamics: In the last three months, InflaRx's EPS estimates have seen two upward revisions and one downward revision, reflecting mixed market perceptions about the company's future performance and increasing uncertainty ahead of the earnings release.
- Compliance Restoration: InflaRx has recently regained Nasdaq compliance as its shares have traded above $1, a development that may enhance market attention on the stock and boost investor confidence.
See More
InflaRx Prices Underwritten Offering of 75M Shares at $2.00 Each
- Offering Pricing: InflaRx announced the pricing of its underwritten offering of 75 million ordinary shares at $2.00 per share, with all shares being sold by the company, indicating a proactive financing strategy in the capital markets.
- Clear Use of Proceeds: The net proceeds from this offering are intended to advance the company's pipeline activities and support working capital and general corporate purposes, reflecting the company's focus on future business development and prudent capital allocation.
- Compliance Restoration: InflaRx has recently regained Nasdaq compliance, with shares trading above $1, which helps enhance investor confidence and may attract more institutional investors' interest.
- Positive Market Response: InflaRx's presentation at Oppenheimer's 36th Annual Healthcare Life Sciences Conference garnered market attention, and combined with its historical earnings data, may lay a foundation for the company's future stock performance.
See More
InflaRx N.V. Prices 75 Million Share Offering at $2.00 Each
- Offering Size and Pricing: InflaRx N.V. announced the pricing of its offering of 75 million ordinary shares at $2.00 per share, expected to close on May 7, 2026, which will provide crucial funding to advance its research pipeline.
- Clear Use of Proceeds: The net proceeds from this offering will be utilized to advance the company's pipeline activities and for working capital, demonstrating the company's commitment to future product development and responsiveness to market demands.
- Investor Participation: The financing attracted participation from both new and existing investors, including TCGX and Farallon Capital, indicating strong market confidence in InflaRx and its appeal in the biopharmaceutical sector.
- Strong Underwriter Team: Guggenheim Securities is acting as the lead underwriter for the offering, with Oppenheimer & Co. and LifeSci Capital also involved, showcasing the company's robust support and expertise in capital markets.
See More
InflaRx Unveils New Pre-Clinical Data on Izicopan
- Low Reactive Metabolite Formation: InflaRx's new data indicates that izicopan exhibits low reactive metabolite formation in human liver microsomes, suggesting a reduced bioactivation-related safety risk, which could enhance its competitive position in the market.
- Comparison with Avacopan: In vitro studies reveal that izicopan's reactive metabolite formation is significantly lower than that of the marketed C5aR1 inhibitor avacopan, with peak areas differing by over 100-fold at early time points, indicating a potential safety advantage for izicopan.
- Pre-Clinical Research Results: Izicopan has demonstrated anti-inflammatory effects in several pre-clinical disease models and showed good tolerability in a Phase 1 study with a maximum dose of 240 mg, with no safety signals reported, highlighting its best-in-class potential.
- Significant Therapeutic Effects: In patients with hidradenitis suppurativa, izicopan led to substantial reductions in abscesses and nodules over four weeks, along with notable improvements in patient-reported pain scores, suggesting its potential for biologic-like efficacy.
See More
InflaRx to Release Q1 2026 Financial Results on May 7
- Earnings Announcement: InflaRx N.V. has announced that it will publish its financial and operational results for Q1 2026 on May 7, 2026, before the market opens, indicating the company's commitment to transparency despite not holding a conference call.
- Innovative Drug Development: The company focuses on developing anti-inflammatory therapeutics targeting the complement system, with its lead product izicopan demonstrating promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and Phase 2a clinical studies, highlighting its potential in treating various inflammatory diseases.
- Technological Edge: InflaRx has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has shown disease-modifying clinical activity and tolerability in multiple studies, further solidifying its competitive position in the biopharmaceutical sector.
- Global Presence: With offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA, InflaRx demonstrates a strategic expansion approach aimed at meeting the growing market demand through innovative therapies.
See More
InflaRx Completes $150 Million Underwritten Offering
- Offering Size: InflaRx N.V. has completed an underwritten offering of 75 million ordinary shares at $2.00 per share, raising a total of $150 million, which reflects strong market confidence in its anti-inflammatory therapies.
- Use of Proceeds: The net proceeds from this offering will be utilized to advance the company's pipeline activities and for general corporate purposes, indicating a proactive expansion strategy aimed at accelerating drug development.
- Investor Participation: The financing attracted participation from both new and existing investors, including TCGX and Farallon Capital, which underscores market recognition of InflaRx's growth potential and strengthens its capital base.
- Underwriting Team: Guggenheim Securities acted as the lead bookrunner for the offering, with Oppenheimer & Co. and LifeSci Capital also participating, demonstrating the company's robust support network in the capital markets.
See More
InflaRx Scheduled to Announce Q1 Earnings on May 7
- Earnings Announcement: InflaRx (IFRX) is set to announce its Q1 earnings on May 7 before market open, with consensus EPS estimate at -$0.17 and revenue estimate at $0.01 million, indicating cautious market sentiment regarding the company's financial performance.
- Historical Performance Review: Over the past year, InflaRx has failed to meet EPS estimates 100% of the time and has only met revenue estimates 25% of the time, highlighting challenges in profitability and revenue growth that could impact investor confidence.
- Estimate Revision Dynamics: In the last three months, InflaRx's EPS estimates have seen two upward revisions and one downward revision, reflecting mixed market perceptions about the company's future performance and increasing uncertainty ahead of the earnings release.
- Compliance Restoration: InflaRx has recently regained Nasdaq compliance as its shares have traded above $1, a development that may enhance market attention on the stock and boost investor confidence.
See More
InflaRx Prices Underwritten Offering of 75M Shares at $2.00 Each
- Offering Pricing: InflaRx announced the pricing of its underwritten offering of 75 million ordinary shares at $2.00 per share, with all shares being sold by the company, indicating a proactive financing strategy in the capital markets.
- Clear Use of Proceeds: The net proceeds from this offering are intended to advance the company's pipeline activities and support working capital and general corporate purposes, reflecting the company's focus on future business development and prudent capital allocation.
- Compliance Restoration: InflaRx has recently regained Nasdaq compliance, with shares trading above $1, which helps enhance investor confidence and may attract more institutional investors' interest.
- Positive Market Response: InflaRx's presentation at Oppenheimer's 36th Annual Healthcare Life Sciences Conference garnered market attention, and combined with its historical earnings data, may lay a foundation for the company's future stock performance.
See More
InflaRx N.V. Prices 75 Million Share Offering at $2.00 Each
- Offering Size and Pricing: InflaRx N.V. announced the pricing of its offering of 75 million ordinary shares at $2.00 per share, expected to close on May 7, 2026, which will provide crucial funding to advance its research pipeline.
- Clear Use of Proceeds: The net proceeds from this offering will be utilized to advance the company's pipeline activities and for working capital, demonstrating the company's commitment to future product development and responsiveness to market demands.
- Investor Participation: The financing attracted participation from both new and existing investors, including TCGX and Farallon Capital, indicating strong market confidence in InflaRx and its appeal in the biopharmaceutical sector.
- Strong Underwriter Team: Guggenheim Securities is acting as the lead underwriter for the offering, with Oppenheimer & Co. and LifeSci Capital also involved, showcasing the company's robust support and expertise in capital markets.
See More
InflaRx Unveils New Pre-Clinical Data on Izicopan
- Low Reactive Metabolite Formation: InflaRx's new data indicates that izicopan exhibits low reactive metabolite formation in human liver microsomes, suggesting a reduced bioactivation-related safety risk, which could enhance its competitive position in the market.
- Comparison with Avacopan: In vitro studies reveal that izicopan's reactive metabolite formation is significantly lower than that of the marketed C5aR1 inhibitor avacopan, with peak areas differing by over 100-fold at early time points, indicating a potential safety advantage for izicopan.
- Pre-Clinical Research Results: Izicopan has demonstrated anti-inflammatory effects in several pre-clinical disease models and showed good tolerability in a Phase 1 study with a maximum dose of 240 mg, with no safety signals reported, highlighting its best-in-class potential.
- Significant Therapeutic Effects: In patients with hidradenitis suppurativa, izicopan led to substantial reductions in abscesses and nodules over four weeks, along with notable improvements in patient-reported pain scores, suggesting its potential for biologic-like efficacy.
See More
InflaRx to Release Q1 2026 Financial Results on May 7
- Earnings Announcement: InflaRx N.V. has announced that it will publish its financial and operational results for Q1 2026 on May 7, 2026, before the market opens, indicating the company's commitment to transparency despite not holding a conference call.
- Innovative Drug Development: The company focuses on developing anti-inflammatory therapeutics targeting the complement system, with its lead product izicopan demonstrating promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and Phase 2a clinical studies, highlighting its potential in treating various inflammatory diseases.
- Technological Edge: InflaRx has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has shown disease-modifying clinical activity and tolerability in multiple studies, further solidifying its competitive position in the biopharmaceutical sector.
- Global Presence: With offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA, InflaRx demonstrates a strategic expansion approach aimed at meeting the growing market demand through innovative therapies.
See More
